Literature DB >> 2908306

Effects of carvedilol on blood pressure in patients with mild to moderate hypertension. A dose response study.

J J McPhillips1, G T Schwemer, D I Scott, M Zinny, D Patterson.   

Abstract

Carvedilol 12.5, 25 and 50 mg was administered once daily for 4 weeks to patients with mild to moderate hypertension. The purpose of the study was to investigate the antihypertensive action of carvedilol when administered once daily and to investigate the pharmacokinetics of carvedilol in patients with mild to moderate hypertension. Measurable decreases in blood pressure (BP) occurred within 1 hour after the first dose. Peak decreases in supine diastolic blood pressure (DBP) were 9.0 +/- 6.8, 15.5 +/- 6.7, 14.7 +/- 10.6 and 22.5 +/- 7.6mm Hg (+/- SD) for the placebo, 12.5, 25 and 50mg carvedilol groups, respectively, and occurred between 3 and 7 hours after the dose. Administration of carvedilol once daily for 4 weeks kept supine DBP below baseline levels for 24 hours. Trough supine DBP after 4 weeks of treatment were 0.6 +/- 6.5, 7.3 +/- 7.9, 8.8 +/- 7.4 and 12.1 +/- 3.8mm Hg (+/- SD) below baseline. Serum levels of carvedilol were proportional to the dose. Peak serum levels were 39 +/- 27, 75 +/- 38 and 161 +/- 131 mu/L for carvedilol 12.5, 25 and 50mg. The kinetics of carvedilol did not change with repeated administration. Carvedilol was well tolerated; 2 patients experienced dizziness associated with postural hypotension after administration of the 50mg dose. Carvedilol 12.5, 25 and 50mg effectively reduced BP for 24 hours when administered once daily.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2908306     DOI: 10.2165/00003495-198800366-00015

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  8 in total

1.  Pharmacokinetics and disposition of carvedilol in humans.

Authors:  G Neugebauer; W Akpan; E von Möllendorff; P Neubert; K Reiff
Journal:  J Cardiovasc Pharmacol       Date:  1987       Impact factor: 3.105

2.  Liquid chromatographic assay and disposition of carvedilol in healthy volunteers.

Authors:  F Varin; L X Cubeddu; J R Powell
Journal:  J Pharm Sci       Date:  1986-12       Impact factor: 3.534

3.  Carvedilol for systemic hypertension.

Authors:  M E Heber; G S Brigden; M P Caruana; A Lahiri; E B Raftery
Journal:  Am J Cardiol       Date:  1987-02-15       Impact factor: 2.778

4.  Clinical pharmacology of carvedilol in normal volunteers.

Authors:  L X Cubeddu; N Fuenmayor; F Varin; V G Villagra; R E Colindres; J R Powell
Journal:  Clin Pharmacol Ther       Date:  1987-01       Impact factor: 6.875

5.  Hemodynamic effects of combined beta-adrenoceptor blockade and precapillary vasodilatation in hypertension.

Authors:  R Eggertsen; R Sivertsson; L Andrén; L Hansson
Journal:  Acta Med Scand Suppl       Date:  1985

6.  Vasodilatory effects of carvedilol and pindolol.

Authors:  S Sundberg; K Tiihonen; A Gordin
Journal:  J Cardiovasc Pharmacol       Date:  1987       Impact factor: 3.105

7.  Pharmacological profile of carvedilol, a compound with beta-blocking and vasodilating properties.

Authors:  K Strein; G Sponer; B Müller-Beckmann; W Bartsch
Journal:  J Cardiovasc Pharmacol       Date:  1987       Impact factor: 3.105

8.  Clinical pharmacologic investigations with carvedilol, a new beta-blocker with direct vasodilator activity.

Authors:  E von Möllendorff; U Abshagen; W Akpan; G Neugebauer; E Schröter
Journal:  Clin Pharmacol Ther       Date:  1986-06       Impact factor: 6.875

  8 in total
  10 in total

1.  Pharmacokinetic and blood pressure effects of carvedilol in patients with chronic renal failure.

Authors:  B K Krämer; K M Ress; C M Erley; T Risler
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

Review 2.  Newer beta blockers and the treatment of hypertension.

Authors:  D McAreavey; R Vermeulen; J I Robertson
Journal:  Cardiovasc Drugs Ther       Date:  1991-06       Impact factor: 3.727

Review 3.  Carvedilol. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders.

Authors:  C J Dunn; A P Lea; A J Wagstaff
Journal:  Drugs       Date:  1997-07       Impact factor: 9.546

4.  Comparison of HERG channel blocking effects of various beta-blockers-- implication for clinical strategy.

Authors:  Kazunobu Kawakami; Toshihisa Nagatomo; Haruhiko Abe; Kan Kikuchi; Hiroko Takemasa; Blake D Anson; Brian P Delisle; Craig T January; Yasuhide Nakashima
Journal:  Br J Pharmacol       Date:  2006-03       Impact factor: 8.739

5.  A simple LC-MS/MS method for pharmacokinetic study of carvedilol and 4/-hydroxyphenyl carvedilol at a low dose.

Authors:  Wanna Eiamart; Nantaporn Prompila; Yaowatree Jumroen; Nonlanee Sayankuldilok; Pajaree Chariyavilaskul; Supeecha Wittayalertpanya
Journal:  Res Pharm Sci       Date:  2022-04-18

Review 6.  Carvedilol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.

Authors:  D McTavish; D Campoli-Richards; E M Sorkin
Journal:  Drugs       Date:  1993-02       Impact factor: 9.546

7.  Clinical pharmacology of carvedilol.

Authors:  B Tomlinson; B N Prichard; B R Graham; R J Walden
Journal:  Clin Investig       Date:  1992

8.  Modulation of K2P 2.1 and K2P 10.1 K(+) channel sensitivity to carvedilol by alternative mRNA translation initiation.

Authors:  J Kisselbach; C Seyler; P A Schweizer; R Gerstberger; R Becker; H A Katus; D Thomas
Journal:  Br J Pharmacol       Date:  2014-08-28       Impact factor: 8.739

Review 9.  Clinical pharmacokinetics and pharmacodynamics of carvedilol.

Authors:  T Morgan
Journal:  Clin Pharmacokinet       Date:  1994-05       Impact factor: 6.447

10.  Cardiovascular pharmacology of K2P17.1 (TASK-4, TALK-2) two-pore-domain K+ channels.

Authors:  Ingo Staudacher; Claudius Illg; Sam Chai; Isabelle Deschenes; Sebastian Seehausen; Dominik Gramlich; Mara Elena Müller; Teresa Wieder; Ann-Kathrin Rahm; Christina Mayer; Patrick A Schweizer; Hugo A Katus; Dierk Thomas
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-07-14       Impact factor: 3.000

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.